id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290195-8uaai9nv	Stebbing, Justin	Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients	2020-05-30		.txt	text/plain	6584	326	46	Furthermore, baricitinib treatment resulted in a significant reduction (p<0.05) from baseline in plasma IL-6 at week 12 in patients with active RA who had an inadequate response to methotrexate from a phase 2b (Tanaka, Emoto et al., 2016) , randomized, placebo-controlled, dose-ranging study (Fig. 1B) . As shown in Figure 3A , all four patients showed improvement with baricitinib treatment in signs and symptoms such as cough, fever, and reduction in plasma IL-6 levels, along with a reduction in the SARS-CoV-2 RNA viral load, as detected by the real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) signal from the nasopharyngeal carriage. Therefore, the impact of baricitinib on the subsequent development of protective humoral and cell-mediated anti-viral immunity in COVID-19 patients must be evaluated in randomized clinical trials (Ottoviani & Stebbing, 2020) . The finding that baricitinib is a potent AAK1/BIKE/GAK inhibitor that may reduce host cell infectivity, along with reaffirmation of its anti-cytokine profile, provide reasons to study this intervention in randomized clinical trials.	./cache/cord-290195-8uaai9nv.txt	./txt/cord-290195-8uaai9nv.txt